title: Inhibition of subcutaneous growth of Ehrlich ascites carcinoma (EAC) tumor by post-immunization with EAC-cell gangliosides and its anti-idiotype antibody in relation to tumor angiogenesis, apoptosis, cell cycle and infiltration of CD4+, CD8+ lymphocytes, NK cells, suppressor cells and APC-cells in tumor.
abstract: Both EAC-tumor associated gangliosides and its anti-idiotype antibody inhibited growth of this tumor significantly. Immuno-histological studies with von Willebrand Factor (vWF) antibody indicated that tumor angiogenesis as determined by expression of vWF decreased in tumors of mice, post-immunized with EAC-cell gangliosides as well as its anti-idiotype antibody. Infiltration of various immune cells of the host in the tumor correlated to some extent with tumor-growth inhibition. Apoptosis study using AnnexinV-FITC and propidium iodide indicated that tumor growth inhibition in mice post-immunized with EAC-gangliosides and its anti-idiotype antibody were due to enhanced apoptosis and cell death. Cell cycle analysis by FACS indicated that EAC-cell associated gangliosides and its anti-idiotype antibody were acting both at the M2 i.e. S and M3 i.e. G2/M phases of the cell cycle to arrest tumor growth.
authors.affiliation: Department of Metabolic Regulation, Chittaranjan National Cancer Institute (CNCI) 37, S. P. Mukherjee Road, Kolkata 700 026, India.
authors.forename: Bipasha
authors.initials: B
authors.lastname: Mondal
authors.forename: Sandip
authors.initials: S
authors.lastname: Saha
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000276:immunology*; D000938:Antigen-Presenting Cells / Q000187:drug effects / Q000276:immunology; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002286:Carcinoma, Ehrlich Tumor / Q000276:immunology / Q000473:pathology / Q000628:therapy; D002453:Cell Cycle / Q000187:drug effects / Q000276:immunology; D045744:Cell Line, Tumor; D005260:Female; D005732:Gangliosides / Q000008:administration & dosage / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D051379:Mice; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines; D005732:Gangliosides